BASF Invests in a New Specialty Amines Plant in the U.S.

BASF is building an alkylethanolamine (AEOA) plant at its U.S. Verbund site in Geismar, Louisiana. The new plant, scheduled to come on line in 2007, complements existing amine production facilities at Geismar. The site currently manufactures some 20 different specialty amines. The new Geismar plant increases BASF’s worldwide production capacities for these important intermediates by about 40 percent. BASF also operates AEOA plants at its Verbund site in Ludwigshafen, Germany.

“We see strong domestic growth opportunity for alkylethanolamines in a number of markets including water treatment, polyurethane catalysts, pharmaceuticals, and coatings,” said Joe Lynch, Business Director for BASF’s Amine Intermediates business in North America. “This investment will allow us to harvest those domestic opportunities, in particular in the polyurethane catalyst and water treatment markets, key targets for BASF amine business.”

Dr. Walter Gramlich, head of the Intermediates Operating Division of the BASF Group, said: “With this plant we reinforce our leading position as a global producer of standard and specialty amines of which alkylethanolamines are a prime example. The Geismar production will make us the world’s only manufacturer of these chemical intermediates with production bases in two regions. As a result we are preparing the basis for further growth of our global amine business which in recent years has been developing very successfully.”

Alkylethanolamines are mainly used as precursors for flocculants applied in water treatment. In addition they are utilized in fabric softener production and in the coatings industry where they act as binders between pigments and resins.

http://www.basf.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.